News
MDXG
3.785
-4.18%
-0.165
MiMedx price target lowered to $7 from $8 at Mizuho
TipRanks · 6h ago
MiMedx (MDXG) Q3 2026 Earnings Call Transcript
The Motley Fool · 13h ago
MiMedx Group, Inc. Reports Third Quarter 2026 Results and $25 million Patent License Agreement
NASDAQ · 19h ago
MiMedx enters $25M patent license agreement with wound care competitor
TipRanks · 20h ago
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 20h ago
MIMEDX announces $25M patent license agreement
Seeking Alpha · 21h ago
MiMedx Group Non-GAAP EPS of -$0.01, revenue of $62.2M misses by $6.52M
Seeking Alpha · 21h ago
MiMedx Group Q3 Adj. EPS $(0.01), Inline, Sales $62.283M Miss $68.553M Estimate
Benzinga · 21h ago
MiMedx Group Inks $25M License Deal With Undisclosed Wound Care Competitor To Settle Allegations Of Infringement Of MiMedx's Patents
Benzinga · 21h ago
Press Release: MIMEDX Announces Third Quarter 2026 Operating & Financial Results
Dow Jones · 21h ago
*MiMedx Group 3Q Loss/Shr 6c >MDXG
Dow Jones · 21h ago
*MiMedx Group 3Q Sales $62.3M >MDXG
Dow Jones · 21h ago
*MiMedx Group 3Q Loss $8.68M >MDXG
Dow Jones · 21h ago
Weekly Report: what happened at MDXG last week (1019-1023)?
Weekly Report · 3d ago
Weekly Report: what happened at MDXG last week (1012-1016)?
Weekly Report · 10/19 10:20
Sanara MedTech/MiMedx deal spread widens on FTC second request.
Seeking Alpha · 10/16 16:08
MiMedx Group merger delayed amid extended FTC review
TipRanks · 10/16 13:36
MiMedx, Sanara received requests for additional information from FTC
TipRanks · 10/16 13:10
MiMedx, Sanara Receive U.S. Federal Trading Commission Second Request For Additional Information, Documentary Materials For Proposed Business Combination
Benzinga · 10/16 13:10
Weekly Report: what happened at MDXG last week (1005-1009)?
Weekly Report · 10/12 10:26
More
Webull provides a variety of real-time MDXG stock news. You can receive the latest news about Mimedx Group Inc through multiple platforms. This information may help you make smarter investment decisions.
About MDXG
MiMedx Group, Inc. is a placental biologics company focused on providing a portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. Its product portfolio categories include Wound Care and Surgical. The Wound Care products include EPIFIX and EPIEFFECT, which are marketed for external use, such as in advanced wound care applications. Its EPICORD, EPICORD Expandable and EPIEFFECT product lines also offer an alternative treatment option to address larger, deeper wounds. Its Surgical and Other product offering includes AMNIOFIX and AMNIOEFFECT, which are used in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. It also offers HELIOGEN, an advanced bovine collagen matrix containing type I and type III collagen that is intended for the management of moderately to heavily exudating wounds and to control minor bleeding.